Cargando…

Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease

AIMS: Despite advances in heart failure (HF) treatment, HF with preserved ejection fraction (HFpEF) remains a health problem with a high mortality rate. HFpEF is composed of diverse phenogroups, of which patients with concomitant renal impairment have worse outcomes. Renal tubular damage (RTD) is as...

Descripción completa

Detalles Bibliográficos
Autores principales: Otaki, Yoichiro, Watanabe, Tetsu, Shimizu, Mari, Tachibana, Shingo, Sato, Junya, Kobayashi, Yuta, Saito, Yuji, Aono, Tomonori, Tamura, Harutoshi, Kato, Shigehiko, Nishiyama, Satoshi, Takahashi, Hiroki, Arimoto, Takanori, Watanabe, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375165/
https://www.ncbi.nlm.nih.gov/pubmed/37264723
http://dx.doi.org/10.1002/ehf2.14378
_version_ 1785078976388005888
author Otaki, Yoichiro
Watanabe, Tetsu
Shimizu, Mari
Tachibana, Shingo
Sato, Junya
Kobayashi, Yuta
Saito, Yuji
Aono, Tomonori
Tamura, Harutoshi
Kato, Shigehiko
Nishiyama, Satoshi
Takahashi, Hiroki
Arimoto, Takanori
Watanabe, Masafumi
author_facet Otaki, Yoichiro
Watanabe, Tetsu
Shimizu, Mari
Tachibana, Shingo
Sato, Junya
Kobayashi, Yuta
Saito, Yuji
Aono, Tomonori
Tamura, Harutoshi
Kato, Shigehiko
Nishiyama, Satoshi
Takahashi, Hiroki
Arimoto, Takanori
Watanabe, Masafumi
author_sort Otaki, Yoichiro
collection PubMed
description AIMS: Despite advances in heart failure (HF) treatment, HF with preserved ejection fraction (HFpEF) remains a health problem with a high mortality rate. HFpEF is composed of diverse phenogroups, of which patients with concomitant renal impairment have worse outcomes. Renal tubular damage (RTD) is associated with the development of HF and chronic kidney disease (CKD). However, the impact of RTD on HF progression in patients with HFpEF and CKD remains unclear. The aim of the present study was to examine whether RTD could predict HF‐related events in patients with HFpEF and CKD. METHODS AND RESULTS: We measured RTD markers, such as urinary β(2)‐microglobulin to creatinine ratio (UBCR) and N‐acetyl‐β‐d‐glucosamidase (NAG) level, in 319 consecutive patients with HFpEF and CKD who were hospitalized for acute HF (49% females, mean age 76 ± 12). Based on previous reports, high UBCR and high NAG levels were defined as UBCR ≥300 μg/gCr and NAG >14.2 U/gCr, respectively. There were 91 HF‐related events, defined as HF hospitalizations or HF deaths, during the median follow‐up period of 5.2 years. The prevalence of high UBCR increased with advancing New York Heart Association functional class and albuminuria. Kaplan–Meier analysis demonstrated that patients with high UBCR had more HF‐related events than those with normal or low UBCR. Multivariate Cox proportional hazards regression analyses demonstrated that high UBCR, but not high NAG level, was an independent predictor of HF‐related events after adjusting for confounding risk factors in patients with HFpEF and CKD (hazard ratio, 2.60; 95% confidence interval, 1.52–4.72; P = 0.0009). UBCR significantly improved the C‐statistic, with a significant net reclassification index and integrated discrimination improvement (0.738 vs. 0.684; P = 0.0244). CONCLUSION: RTD, as assessed by a high UBCR, was associated with the severity and clinical outcomes of HFpEF and CKD, indicating that it could be a feasible marker for HF progression.
format Online
Article
Text
id pubmed-10375165
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103751652023-07-29 Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease Otaki, Yoichiro Watanabe, Tetsu Shimizu, Mari Tachibana, Shingo Sato, Junya Kobayashi, Yuta Saito, Yuji Aono, Tomonori Tamura, Harutoshi Kato, Shigehiko Nishiyama, Satoshi Takahashi, Hiroki Arimoto, Takanori Watanabe, Masafumi ESC Heart Fail Original Articles AIMS: Despite advances in heart failure (HF) treatment, HF with preserved ejection fraction (HFpEF) remains a health problem with a high mortality rate. HFpEF is composed of diverse phenogroups, of which patients with concomitant renal impairment have worse outcomes. Renal tubular damage (RTD) is associated with the development of HF and chronic kidney disease (CKD). However, the impact of RTD on HF progression in patients with HFpEF and CKD remains unclear. The aim of the present study was to examine whether RTD could predict HF‐related events in patients with HFpEF and CKD. METHODS AND RESULTS: We measured RTD markers, such as urinary β(2)‐microglobulin to creatinine ratio (UBCR) and N‐acetyl‐β‐d‐glucosamidase (NAG) level, in 319 consecutive patients with HFpEF and CKD who were hospitalized for acute HF (49% females, mean age 76 ± 12). Based on previous reports, high UBCR and high NAG levels were defined as UBCR ≥300 μg/gCr and NAG >14.2 U/gCr, respectively. There were 91 HF‐related events, defined as HF hospitalizations or HF deaths, during the median follow‐up period of 5.2 years. The prevalence of high UBCR increased with advancing New York Heart Association functional class and albuminuria. Kaplan–Meier analysis demonstrated that patients with high UBCR had more HF‐related events than those with normal or low UBCR. Multivariate Cox proportional hazards regression analyses demonstrated that high UBCR, but not high NAG level, was an independent predictor of HF‐related events after adjusting for confounding risk factors in patients with HFpEF and CKD (hazard ratio, 2.60; 95% confidence interval, 1.52–4.72; P = 0.0009). UBCR significantly improved the C‐statistic, with a significant net reclassification index and integrated discrimination improvement (0.738 vs. 0.684; P = 0.0244). CONCLUSION: RTD, as assessed by a high UBCR, was associated with the severity and clinical outcomes of HFpEF and CKD, indicating that it could be a feasible marker for HF progression. John Wiley and Sons Inc. 2023-06-01 /pmc/articles/PMC10375165/ /pubmed/37264723 http://dx.doi.org/10.1002/ehf2.14378 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Otaki, Yoichiro
Watanabe, Tetsu
Shimizu, Mari
Tachibana, Shingo
Sato, Junya
Kobayashi, Yuta
Saito, Yuji
Aono, Tomonori
Tamura, Harutoshi
Kato, Shigehiko
Nishiyama, Satoshi
Takahashi, Hiroki
Arimoto, Takanori
Watanabe, Masafumi
Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease
title Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease
title_full Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease
title_fullStr Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease
title_full_unstemmed Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease
title_short Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease
title_sort renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375165/
https://www.ncbi.nlm.nih.gov/pubmed/37264723
http://dx.doi.org/10.1002/ehf2.14378
work_keys_str_mv AT otakiyoichiro renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT watanabetetsu renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT shimizumari renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT tachibanashingo renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT satojunya renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT kobayashiyuta renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT saitoyuji renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT aonotomonori renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT tamuraharutoshi renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT katoshigehiko renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT nishiyamasatoshi renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT takahashihiroki renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT arimototakanori renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease
AT watanabemasafumi renaltubulardamageandclinicaloutcomeinheartfailurewithpreservedejectionfractionandchronickidneydisease